Bioshore Ventures
Overview
Bioshore Ventures intelligently and knowledgably allocates capital to drive breakthrough MedTech innovation via a highly tax-efficient hybrid fund structure. Invest alongside leading Australian health care professionals and MedTech entrepreneurs.
The fund has been established to take advantage of Australia and NZ’s world-class medical technology sector, addressing the gap between our thriving medical research environment but significantly under-resourced product development ecosystem. Led by a team of seasoned industry professionals with an unparalleled track record of investing in and commercialising medical technologies, Bioshore Ventures has a dedicated focus on investing in best-in-class medical devices. In addition to our portfolio companies securing a host of non-dilutive grants, the fund has been structured to take advantage of the federal government's ESVCLP provisions, ensuring highly tax-effective returns to our LP’s.
Problem and Solution
Ut dignissim eget felis non ultrices. Vivamus fermentum erat at velit varius molestie.
Duis vitae mi neque.
Donec tincidunt, dolor luctus lobortis ultrices, turpis eros cursus turpis, maximus tempor lectus lectus vel
Competitive Advantage
Ut dignissim eget felis non ultrices. Vivamus fermentum erat at velit varius molestie.
Duis vitae mi neque. Donec tincidunt, dolor luctus lobortis ultrices, turpis eros cursus turpis, maximus tempor lectus lectus vel diam.
Proin neque lacus, semper vel ex at, eleifend rhoncus est.
Cras non nisi urna. Sed feugiat dignissim erat, eget convallis nisl blandit a.
Nullam fringilla diam eget dui placerat fermentum. Maecenas malesuada viverra leo eu bibendum. Nam vulputate enim velit, eu pretium justo tristique ac.
Nam vitae varius augue. Nam pharetra facilisis elementum. Sed nisl risus, vestibulum ut velit at, dapibus sagittis arcu.
Nullam sed dolor suscipit,
Current Shareholders & Investors
Pellentesque tempor a risus in elementum. Proin malesuada mauris et mauris bibendum laoreet.
Vivamus maximus nulla volutpat, ornare lorem a, vulputate enim. In dui nisl, vestibulum eu f
Current & Future Projects
Proin auctor bibendum ex, non condimentum tortor sodales vitae. Ut feugiat at lorem accumsan consequat.
Suspendisse ac condimentum ipsum, sit amet auctor dui. Aliquam pretium justo in commodo varius.
Pellentesque elementum felis non urna vulputate, non posuere metus suscipit.
Aenean lacinia id quam a lobortis. Cras nibh lorem, vulputate eget purus elementum, pharetra condimentum eli
See more exiting opportunities on CapitalHQ
Pictor
Powering diagnostics with protein signatures. Pictor is transforming health with its patented platform providing accessible, affordable, and scalable diagnostic solutions across the human and animal health verticals. PictArray can detect up to 10 diseases or biomarkers from one small serum, milk,...
ProxyTwin
ProxyTwin™ amplifies expertise. ProxyTwin is a digital twin that works for experts so they can help more people. We create advanced digital replicas of real individuals, enabling them to virtually attend meetings, deliver messages, and hold thousands of interactions simultaneously. Recently...
HorizonTwo Capital Partners
HorizonTwo Capital Partners is a private equity firm that specialises in advanced manufacturing companies.
The Insides Company
First-in-class medtech for intestinal failure. Seeking remaining $1M of a $5M round, on a AUD$17.2M pre-money valuation.
DCARB
We are aiming to raise $CAD5M to fund the ongoing commercialisation of the D100 unit, including working capital to fund the expected growth in sales, and a field trial of the DArc unit. This follows a successful Series B round completed in mid-2023.
Grabba Technologies Pty Ltd
Advanced manufacturer of biometric identity authorisation products and electronics supplier to defence industry. We invite expressions of interest for up to $10.0M in growth capital.
Backed By Leading Investment Groups and Family Offices
